Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169)

Asma Mostafapour; Fereshteh Asgharzadeh; Seyedeh Elnaz Nazari; Moein Eskandari; Niloufar Naghibzadeh; Javad Baharara; Amir Avan; Seyed Mahdi Hassanian; Majid Khazaei

doi:10.61186/phypha.28.4.494

Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169)

Asma Mostafapour
, Fereshteh Asgharzadeh
, Seyedeh Elnaz Nazari
, Moein Eskandari
, Niloufar Naghibzadeh
, Javad Baharara
, Amir Avan
, Seyed Mahdi Hassanian
, Majid Khazaei^*

^*Corresponding author for this work

Islamic Azad University
Mashhad University of Medical Sciences

Research output: Contribution to journal › Erratum/Corrigendum › Academic

15 Downloads (Pure)

Abstract

The authors regret an incorrect version of Fig. 2 was included in the original article. The correct version of Fig. 2 is presented below. (Figure presented).

Original language	English
Pages (from-to)	494-495
Journal	Physiology and Pharmacology (Iran)
Volume	28
Issue number	4
DOIs	https://doi.org/10.61186/phypha.28.4.494
Publication status	Published - 1 Dec 2024
Externally published	Yes

Access to Document

10.61186/phypha.28.4.494

Corrigendum.pdfFinal published version, 337 KB

Fingerprint

Dive into the research topics of 'Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169)'. Together they form a unique fingerprint.

Cite this

Mostafapour, A., Asgharzadeh, F., Nazari, S. E., Eskandari, M., Naghibzadeh, N., Baharara, J., Avan, A., Hassanian, S. M., & Khazaei, M. (2024). Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169). Physiology and Pharmacology (Iran), 28(4), 494-495. https://doi.org/10.61186/phypha.28.4.494

Mostafapour, Asma ; Asgharzadeh, Fereshteh ; Nazari, Seyedeh Elnaz et al. / Corrigendum : The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169). In: Physiology and Pharmacology (Iran). 2024 ; Vol. 28, No. 4. pp. 494-495.

@article{05f2e49ccf4340358436d8bd352571a4,

title = "Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169)",

abstract = "The authors regret an incorrect version of Fig. 2 was included in the original article. The correct version of Fig. 2 is presented below. (Figure presented).",

author = "Asma Mostafapour and Fereshteh Asgharzadeh and Nazari, \{Seyedeh Elnaz\} and Moein Eskandari and Niloufar Naghibzadeh and Javad Baharara and Amir Avan and Hassanian, \{Seyed Mahdi\} and Majid Khazaei",

year = "2024",

month = dec,

day = "1",

doi = "10.61186/phypha.28.4.494",

language = "English",

volume = "28",

pages = "494--495",

journal = "Physiology and Pharmacology (Iran)",

issn = "2476-5236",

publisher = "Iranian Society of Physiology and Pharmacology",

number = "4",

}

Mostafapour, A, Asgharzadeh, F, Nazari, SE, Eskandari, M, Naghibzadeh, N, Baharara, J, Avan, A, Hassanian, SM & Khazaei, M 2024, 'Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169)', Physiology and Pharmacology (Iran), vol. 28, no. 4, pp. 494-495. https://doi.org/10.61186/phypha.28.4.494

Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169). / Mostafapour, Asma; Asgharzadeh, Fereshteh; Nazari, Seyedeh Elnaz et al.
In: Physiology and Pharmacology (Iran), Vol. 28, No. 4, 01.12.2024, p. 494-495.

Research output: Contribution to journal › Erratum/Corrigendum › Academic

TY - JOUR

T1 - Corrigendum

T2 - The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169)

AU - Mostafapour, Asma

AU - Asgharzadeh, Fereshteh

AU - Nazari, Seyedeh Elnaz

AU - Eskandari, Moein

AU - Naghibzadeh, Niloufar

AU - Baharara, Javad

AU - Avan, Amir

AU - Hassanian, Seyed Mahdi

AU - Khazaei, Majid

PY - 2024/12/1

Y1 - 2024/12/1

N2 - The authors regret an incorrect version of Fig. 2 was included in the original article. The correct version of Fig. 2 is presented below. (Figure presented).

AB - The authors regret an incorrect version of Fig. 2 was included in the original article. The correct version of Fig. 2 is presented below. (Figure presented).

UR - https://www.scopus.com/pages/publications/85217236466

U2 - 10.61186/phypha.28.4.494

DO - 10.61186/phypha.28.4.494

M3 - Erratum/Corrigendum

SN - 2476-5236

VL - 28

SP - 494

EP - 495

JO - Physiology and Pharmacology (Iran)

JF - Physiology and Pharmacology (Iran)

IS - 4

ER -

Mostafapour A, Asgharzadeh F, Nazari SE, Eskandari M, Naghibzadeh N, Baharara J et al. Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169). Physiology and Pharmacology (Iran). 2024 Dec 1;28(4):494-495. doi: 10.61186/phypha.28.4.494

Corrigendum: The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice, (Physiol Pharmacol, (2024), 28, (169-179), 10.61186/phypha.28.2.169)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this